Mario E. Lacouture, MD


Director, Oncodermatology Program

Mario E. Lacouture, MD
Locations Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Telephone New Patient Appointments Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Telephone Office Phone Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

About Me

I am a board-certified dermatologist with special interest in dermatologic conditions that result from cancer treatments. My clinical career has been focused on the recognition and management of side effects affecting the skin, hair, and nails of cancer patients and survivors. These effects can occur as a consequence of chemotherapy, radiation therapy, or therapeutic transplants.

To ensure that dermatologic side effects do not affect quality of life and the consistent administration of anticancer therapies, I founded the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary effort comprising patient care, education, and research. This clinical program is unique in that it provides pre-treatment counseling and preventive efforts in order to minimize the development of side effects, as well as rapid attention to those patients who develop them. Close communication with treating oncologists ensures that interventions against side effects do not affect the effectiveness of cancer treatments. In summary, the ultimate goal is to ensure the best dermatology-related quality of life and benefit from anticancer treatments.

My research focuses on major components of dermatologic side effects: the accurate description and severity grading; the effects on quality of life; the identification of factors that place individuals at higher risk; and the development of treatments. A basic tenet of this research is in exploring new skin treatments that do not affect the effectiveness of anticancer drugs. For example, we use topical medicines in the face or regional cooling of hands or feet to prevent or treat drug-induced side effects in these areas. A new field being investigated is on dermatologic effects of cancer therapies in long-term cancer survivors, the first step towards ensuring long-term skin health after cancer therapies.

In addition to my role in the treatment of dermatologic conditions in cancer patients and survivors, I am Co-chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer, an international organization devoted to the understanding of side effects in cancer patients.

  • Clinical Expertise: Dermatologic Side Effects of Cancer Treatment
  • Awards and Honors: Castle Connolly: New York Magazine Top Doctors (2014-2018)
  • Languages Spoken: English; Italian; Spanish
  • Education: MD, Javeriana University
  • Residencies: Dermatology - University of Chicago
  • Fellowships: Brigham and Women's Hospital
  • Board Certifications: Dermatology

See My Colleagues


Visit PubMed for a full listing of Mario E. Lacouture’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.